SOX方案和GP方案对晚期三阴乳腺癌患者临床疗效及CA153、CEA水平的影响

发布时间：2018-06-21 21:28

本文选题：奥沙利铂 + 吉西他滨　；参考：《东南大学学报(医学版)》2017年05期

【摘要】：目的:探讨奥沙利铂联合替吉奥(SOX方案)和吉西他滨联合顺铂(GP方案)对晚期三阴乳腺癌患者临床疗效及糖类抗原153(CA153)、癌胚抗原(CEA)水平的影响。方法:选取2012年8月至2015年8月盐城市第一人民医院的134例晚期三阴乳腺癌患者作为研究对象,根据随机数字表法分为A组和B组,每组各67例,A组患者给予SOX方案治疗,B组患者给予GP方案治疗,对比分析两组患者近期疗效、远期疗效、不良反应以及血清CA153和CEA水平。结果:A组患者总有效率(RR)和疾病控制率(DCR)分别为35.82%和68.66%,B组患者RR和DCR分别为34.33%和65.67%,两组差异均无统计学意义(P0.05);A组和B组患者中位疾病进展时间分别为9.7个月和8.2个月,差异具有统计学意义(P=0.031);A组和B组患者1年生存率分别为70.15%和64.18%,差异无统计学意义(P=0.462);A组和B组患者中位总生存时间分别为20.1个月和19.4个月,差异无统计学意义(P=0.289)。两组患者常见不良反应相似,其中A组患者手足综合征、肝功能损伤、腹泻以及外周神经毒性发生率分别为44.78%、46.27%、40.30%和58.21%,均显著高于B组患者(分别为0、23.88%、17.91%和14.93%),差异均有统计学意义(P0.05);A组患者皮疹、恶心/呕吐、血小板降低和肾脏毒性发生率分别为19.40%、41.79%、41.79%和7.46%,均显著低于B组患者(分别为37.31%、70.15%、65.67%和28.36%),差异均有统计学意义(P0.05);治疗后,两组患者CA153、CEA水平与治疗前相比均显著降低,差异具体统计学意义(P0.05);且治疗后两组患者CA153、CEA水平比较,差异均无有统计学意义(P0.05)。结论:临床晚期三阴乳腺癌患者采用SOX方案和GP方案治疗,均可取得理想疗效,且耐受性较好。
[Abstract]:Objective: to investigate the effects of oxaliplatin combined with tigeoxime Sox regimen and gemcitabine combined with cisplatin GP regimen on the clinical efficacy and the level of carbohydrate antigen 153 CA153 carcinoembryonic antigen (CEA) in patients with advanced triple negative breast cancer. Methods: 134 patients with advanced triple yin breast cancer from August 2012 to August 2015 were randomly divided into two groups: group A and group B. 67 patients in each group were treated with Sox regimen and group B were treated with GP regimen. The short-term efficacy, long-term effect, adverse reaction and serum CA153 and CEA levels were compared and analyzed. Results the total effective rate (RRR) and disease control rate (DCR) were 35.82% in group A and 34.33% in group B and 65.67% in group B, respectively. There was no significant difference between the two groups in the median disease progression time of group A and group B were 9.7 months and 8.2 months, respectively. The 1-year survival rates of group A and group B were 70.15% and 64.18, respectively. The median total survival time of group A and group B were 20.1 months and 19.4 months, respectively. The common adverse reactions of the two groups were similar. Group A had hand and foot syndrome and liver function injury. The incidence of diarrhea and peripheral neurotoxicity were 44.78% and 58.21%, respectively, which were significantly higher than those in group B (17.91% and 14.933%, respectively). The incidence of thrombocytopenia and nephrotoxicity were 19.40% 41.79% and 7.46%, respectively, which were significantly lower than those in group B (37.31%, 70.15%, 65.67% and 28.3636%, respectively). The difference was statistically significant (P 0.05), and there was no significant difference in CEA level between the two groups after treatment (P 0.05). Conclusion: patients with advanced triple yin breast cancer can be treated with Sox regimen and GP regimen.
【作者单位】：盐城卫生职业技术学院;盐城市第一人民医院;
【分类号】：R737.9

【相似文献】